Pharmion's Amrubicin, Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Nov. 9, 2007 - Pharmion Corporation (Nasdaq: PHRM) today released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company's third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC.... Pharmion's Press Release -

Pharmion , Phase 3 Study of Amrubicin in Small Cell Lung Cancer

Oct. 17 , 2007 - Pharmion Corporation (Nasdaq: PHRM) announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway... Pharmion's Press Release-